SINOMAB BIO-B (03681) announced that on March 24, 2026, the company granted 11.5748 million share options to two eligible individuals under the 2022 Share Option Scheme. These options grant the recipients the right to subscribe for a total of 11.5748 million new shares of the company, which will be effective upon acceptance by the recipients.